The FDA has approved RHA Redensity Eye, a crosslinked hyaluronic acid filler from Revance and Teoxane, for correction of under-eye hollowing and volume loss. The indication extends the RHA line—known for its resilient, dynamic properties—into the periorbital space, a technically demanding zone where filler migration and Tyndall effect are persistent concerns.
Injectables
RHA Redensity Eye Wins FDA Nod for Under-Eye Hollows
Revance and Teoxane's crosslinked HA filler gains clearance for periorbital volume loss—expanding the RHA platform beyond lips and cheeks.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
RHA Redensity Eye extends the dynamic-filler platform into the periorbital space.
RHA's rheology profile, engineered to mimic native HA behavior during facial movement, addresses a real clinical friction point: traditional fillers often appear static or overfilled in the tear trough. The under-eye market remains fragmented—Restylane, Juvéderm, and Belotero each hold territory—but a purpose-built formulation for that anatomy could shift preference. Revance now has a three-product injectable suite (Nuceiva toxin, RHA for lips/cheeks, and now RHA Redensity Eye), strengthening its position as an alternative to AbbVie and Galderma for practices seeking non-Allergan/non-Galderma platforms.
Source: original report ↗
Frequently asked questions
What is RHA Redensity Eye and how does it differ from other under-eye fillers?
RHA Redensity Eye is a crosslinked hyaluronic acid filler from Revance and Teoxane designed specifically for periorbital volume loss and under-eye hollowing. It uses a rheology profile engineered to mimic natural HA behavior during facial movement, reducing the static appearance and Tyndall effect concerns common with traditional fillers like Restylane and Juvéderm in the tear trough area.
Is RHA Redensity Eye FDA approved for under-eye treatment?
Yes, the FDA has approved RHA Redensity Eye for correction of under-eye hollowing and volume loss. This approval extends the RHA product line—previously available for lips and cheeks—into the technically demanding periorbital space.
What companies make RHA Redensity Eye?
RHA Redensity Eye is a collaboration between Revance and Teoxane. Revance now offers a three-product injectable suite including Nuceiva toxin, RHA for lips and cheeks, and RHA Redensity Eye for under-eye treatment.
What is Tyndall effect and why is it a concern with under-eye fillers?
The Tyndall effect is a bluish discoloration that occurs when filler particles scatter light, creating a visible hue beneath thin periorbital skin. RHA Redensity Eye's formulation is engineered to address this persistent concern in the tear trough, where traditional fillers are more prone to migration and optical distortion.
How does RHA Redensity Eye fit into Revance's product portfolio?
RHA Redensity Eye completes Revance's three-product injectable platform alongside Nuceiva (botulinum toxin) and RHA for lips and cheeks. This positions Revance as a comprehensive alternative to AbbVie and Galderma for practices seeking non-Allergan and non-Galderma injectable options.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.